Alfuzosin hydrochloride transdermal films: Evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters

International Braz J Urol

Volumn 35, Issue 6, 2009, Pages 716-729

  Pattnaik, Satyanarayan ^a   Swain, Kalpana ^a   Choudhury, Parthagan ^a   Acharya, Pradeepta K ^a   Mallick, Subrata ^b  

^a Department of Pharmaceutics   (India)

^b SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

Administration; Alfuzosin hydrochloride; Cutaneous; Polymers

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL; ARTICLE; CADAVER; DRUG DELIVERY SYSTEM; EVALUATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; PERMEABILITY; RABBIT; SKIN ABSORPTION; THERMODYNAMICS;

ADMINISTRATION, CUTANEOUS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; CADAVER; DRUG DELIVERY SYSTEMS; HUMANS; PERMEABILITY; QUINAZOLINES; RABBITS; SKIN ABSORPTION; THERMODYNAMICS;

EID: 77949523008     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382009000600010     Document Type: Article

References (20)

1. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991; 338: 469-71.
2. Rossi C, Kortmann BB, Sonke GS, Floratos DL, Kiemeney LA, Wijkstra H, et al.: alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol. 2001; 165: 38-41.
3. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36: 1-13.
4. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002; 62: 633-53.
5. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001; 58 (6 Suppl 1): 55-63; discussion 63-4.
6. Liu Q, Fassihi R: Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm. 2008; 348: 27-34.
7. Barry BW: Breaching the skin's barrier to drugs. Nat Biotechnol. 2004; 22: 165-7.
8. Ramírez-Campos M, Villafuerte-Roble L: Effect of Formulation Variables on Verapamil Hydrochloride Release from Hydrated HPMC Matrices. Rev Soc Quím Méx. 2004; 48: 326-31.
9. Arora P, Mukherjee B: Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002; 91: 2076-89.
10. Swain K, Pattnaik S, Mallick S, Chowdary KA: Influence of hydroxypropyl methylcellulose on drug release pattern of a gastroretentive floating drug delivery system using a 3(2) full factorial design. Pharm Dev Technol. 2009; 14: 193-8.
11. Grass GM, Robinson JR: Mechanisms of corneal drug penetration. I: In vivo and in vitro kinetics. J Pharm Sci. 1988; 77: 3-14.
12. Kawazu K, Midori Y, Shiono H, Ota A: Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol. 1999; 51: 797-801.
13. Draize JH, Woodard G, Calvery HO: Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944; 82: 377-90.
14. Arora P, Mukherjee B: Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002; 91: 2076-89.
15. Pattnaik S, Swain K, Mallick S: Influence of polymeric system and loading dose on drug release from alfuzosin hydrochloride transdermal films. Lat. Am. J. Pharm. 2009; 28: 62-9.
16. Segurola J, Allen NS, Edge M, McMahon A: Design of eutectic photoinitiator blends for UV/visible curable acrylated printing inks and coatings. Prog Org Coat. 1999; 37: 23-37.
17. Bodmeier R, Paeratakul O: Evaluation of drug-containing polymer films prepared from aqueous latexes. Pharm Res. 1989; 6: 725-30.
18. Guyot M, Fawaz F: Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm. 2000; 204: 171-82.
19. Barat R, Srinatha A, Pandit JK, Anupurba S, Mittal N: Chitosan inserts for periodontitis: influence of drug loading, plasticizer and crosslinking on in vitro metronidazole release. Acta Pharm. 2007; 57: 469-77.
20. Bhardwaj SB, Shukla AJ, Collins CC: Effect of varying drug loading on particle size distribution and drug release kinetics of verapamil hydrochloride microspheres prepared with cellulose esters. J Microencapsul. 1995; 12: 71-81.